| Opioids |
1 |
0.79 |
| Schizophrenia |
0 |
0.73 |
| Receptors |
0 |
0.56 |
| Weight Gain |
0 |
0.51 |
| Atypical Antipsychotics |
0 |
0.36 |
| Antipsychotics |
0 |
0.34 |
| Weight Management |
0 |
0.34 |
| Pharmacokinetics |
0 |
0.3 |
| Metabolism |
0 |
0.21 |
| Xerostomia |
0 |
0.18 |
| Dopamine |
0 |
0.13 |
| Food and Drug Administration (FDA) |
0 |
0.13 |
| Inpatient Care |
0 |
0.13 |
| Mouth |
0 |
0.13 |
| Smoking |
0 |
0.13 |
| Dentistry and Oral Health |
0 |
0.12 |
| Dopamine Agonists |
0 |
0.12 |
| Hypertension |
0 |
0.1 |
| Drug Interaction |
0 |
0.09 |
| Electrocardiogram (ECG) |
0 |
0.09 |
| Gamma aminobutyric acid |
0 |
0.09 |
| Hemoglobin |
0 |
0.09 |
| Hemoglobin A1c |
0 |
0.09 |
| Mania |
0 |
0.09 |
| Pharmacodynamics |
0 |
0.09 |
| Electrophysiology |
0 |
0.08 |
| Tobacco Cessation |
0 |
0.08 |
| Arrhythmia |
0 |
0.07 |
| ADHD |
0 |
0.06 |
| Constipation |
0 |
0.06 |
| Orthostatic Hypotension |
0 |
0.06 |
| Bipolar Disorder |
0 |
0.05 |
| Antihypertensive Agents |
0 |
0.04 |
| Benzodiazepines |
0 |
0.04 |
| Body Mass Index |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Central Nervous System |
0 |
0.04 |
| Clinical Research |
0 |
0.04 |
| Drug Reaction |
0 |
0.04 |
| End-Stage Renal Disease |
0 |
0.04 |
| Eosinophilia |
0 |
0.04 |
| Hematology |
0 |
0.04 |
| Histamine |
0 |
0.04 |
| Hypotension |
0 |
0.04 |
| Ileus |
0 |
0.04 |
| Impairment |
0 |
0.04 |
| Levodopa |
0 |
0.04 |
| Prostate |
0 |
0.04 |
| Renal Disease |
0 |
0.04 |
| Tachycardia |
0 |
0.04 |
| Tissue |
0 |
0.04 |
| Tolerance |
0 |
0.04 |
| Urinary Retention |
0 |
0.04 |
| Young Adult |
0 |
0.04 |
| Cardiovascular Risk Management |
0 |
0.03 |
| Depression |
0 |
0.03 |
| Headache |
0 |
0.03 |
| Lipids Management |
0 |
0.03 |
| Renal Failure |
0 |
0.03 |